All News

question-mark-1872634_640.jpg

ICYMI: What to do about pre-clinical RA?

Robert Chao, MD

RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis, especially what to do regarding pre-clinical RA.

Dr. Kevin Deane started the discussion by mapping out a very complex course of RA, beginning with a person’s genetic and environmental risk factors. What are Dr. Deane’s recommendations for management of pre-RA patients?

Read Article
RheumNow Podcast square

National Population Insights (4.28.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.

Read Article
Giants,women,rheumatology

25 Great Women in Rheumatology

Jack Cush, MD

This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? This was prompted by a smart article in Annals of Rheumatic Disease written by Drs. Tuhina Neogi (Boston) and Nicola Dalbeth (N. Zealand), entitled "Where are the women ‘Heroes and Pillars of Rheumatology’?

Read Article
diet.better.jpg

NY Times on Arthritis Prevention

Jack Cush, MD

A reader question ("Ask Well") to the New York times wonders "is arthritis avoidable"?



A recent survey suggests that up to 60% of adults have been told by an HCP they had some form of arthritis.

Read Article
RheumNow Podcast square

Want to Go Far, Go Together (4.21.2023)

Jack Cush, MD

This week on the podcast Dr. Jack Cush reviews the news, regulatory announcements and novel journal reports including a profile on pseudogout, the safety of immune checkpoint inhibitors in RA patients and the diagnostic importance of neutrophils.

Read Article
arthritis.RA_.Xray_.hands_.jpg (keep)

Immune Checkpoint Inhibitor Safety with Pre-existing Rheumatoid Arthritis

Jack Cush, MD

Lancet Rheumatology has published a retrospective analysis showing patients receiving immune checkpoint inhibitors (ICI) for cancer have the same outcomes (mortality and severe immune-related adverse events (irAEs)) even when they have pre-existing rheumatoid arthritis (RA).

Read Article
QD Clinic - Audience RA Questions from RNL23 Audience Questions & Answers from RNL23 on Rheumatoid Arthritis https://t.co/vh1Tzstbwl https://t.co/IUXfAlzPoE

Links:

Dr. John Cush RheumNow ( View Tweet)
UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors: - RE: tofacitinib, abrocitinib, baricitinib, upadacitinib & filgotinib use in chr inflammatory Dz. - avoid JAKi if no suitable alternative: age >=65, smokers, CV/CA Hx https://t.co/Y1vZPHPEPN https://t.co/odovKWebFV

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us this Tuesday for our the start of our May Tuesday Night Rheumatology focusing on Rheumatoid Arthritis: Revolutionary Advances in Therapy https://t.co/TbNYaGJ3sk https://t.co/DiJwjvUX1d

Links:

Dr. John Cush RheumNow ( View Tweet)
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/wfrlAcij8x https://t.co/OvqKrHw5Wu

Links:

Dr. John Cush RheumNow ( View Tweet)
Analysis of 14,958 RA pts in Japans National Database of Rheumatic Diseases (NinJa) shows women had higher DAS28-ESR values than males, despite no obvious difference in other indices or disease activity categories. https://t.co/PYsTGnejOF https://t.co/AqOiiZm3uI

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Jeff Sparks talks sex differences and rheumatoid arthritis associated interstitial lung disease. https://t.co/asUrfXw2Y1 https://t.co/oLwi8BvquO

Links:

Dr. John Cush RheumNow ( View Tweet)
Immune Checkpoint Inhibitor Safety with Pre-existing Rheumatoid Arthritis Lancet Rheumatology has published a retrospective analysis showing patients receiving ICI for cancer have the same outcomes even when they have pre-existing RA. https://t.co/aFNZX5YaLD https://t.co/ZY9Ie8TOPc

Links:

Dr. John Cush RheumNow ( View Tweet)
Brigham review (2018-2022) of 47 CPPD pts: M=F, mean age 72 yrs 68% w/ acute CPP arthritis 40% w/ CPP inflammatory arthritis 62% w/ OA with CPPD. Compared to Gout, CPPD Significant unmet Rx need & lower RAPID3 (8.1 vs 12.1) https://t.co/cLNjGxi6qF https://t.co/76PoepxRjR

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us 4/25 as we conclude our Women in Rheumatology campaign by focusing on what's next. Our panelists will recap the challenges addressed this month and discuss a strategy to suppot women in rheumatology. https://t.co/DP4S2hf5Tz @uptoTate @KDAO2011 @gwenesta_melton https://t.co/rcglaZxqoF

Links:

Dr. John Cush RheumNow ( View Tweet)
TNR: Private Practice & Academia In this session, our panelists addressed the big questions of: "How do I choose between private practice and academia?" and "How do I advance in my career?". https://t.co/yMJ5mCtSXX @KDAO2011 https://t.co/eeFYkLYsAh

Links:

Dr. John Cush RheumNow ( View Tweet)
Immune Checkpoint Inhibitor Safety with Pre-existing Rheumatoid Arthritis Lancet Rheumatology has published a retrospective analysis showing patients receiving ICI for cancer have the same outcomes even when they have pre-existing RA. https://t.co/Tjj827nPTT https://t.co/nBBgI9wpjR

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 9558 pts found significant associations betw migraine and CTS Median nerve decompression (OR, 1.3) & multiple nerve decompressions (OR, 1.7). Also assoc w/ migraine: psych dz, RA, CVS, hypothyroid, HTN, COPD https://t.co/cIdkACHGwB https://t.co/VO3VqujzSQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Real world interchangeabilty study compared rituximab to biosimilar ( CT-P10) in 128 Rheum pts (CT-P10= 64; RTX= 64), with 41% of pts switched from RTX to CT-P10. Both Rx had Comparable Gr 2 infuxion Rxs, infection #s & hypogammaglobulinemia (p > 0.05) https://t.co/RNxt7Xn7MJ https://t.co/u3yJNQQIMC

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective study on prescribing by male vs female RHEUMs, found that women (in private practice, >10 yrs) were less likely to be High steroid prescribers. RA Pts more likely to Rx steroids = male sex, >prior biologics, opioid use, w/ comorbidities & freq infx https://t.co/eO3yJRCfOR
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×